1986
DOI: 10.1111/j.1471-0528.1986.tb07928.x
|View full text |Cite
|
Sign up to set email alerts
|

Clinical aspects of LHRH analogues in gynaecology: a review

Abstract: LHRH agonists are synthetic peptide analogues of hypothalamic luteinizing hormone releasing hormone (LHRH) with superior potency and longer duration of gonadotrophin release. Paradoxically, repeated administration causes pituitary desensitization with diminished gonadotrophin and oestradiol secretion. A state of hypogonadotrophic hypogonadism is reversibly induced; plasma oestrogen can be reduced to castrate levels. LHRH agonists reliably induce anovulation but are unlikely to replace existing contraceptive me… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
7
0

Year Published

1988
1988
2003
2003

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 49 publications
(7 citation statements)
references
References 117 publications
0
7
0
Order By: Relevance
“…There is concern that increased long-term use of LHRH analogues may be associated with unwanted sequelae of hypoestrogenism, such as osteopaenia (McLachlan et al 1986;Gudmundsson et al 1987;Henzl et al 1988). Our present findings in the rat con¬ firm, by direct skeletal analysis, work in women which suggests that LHRH agonists cause bone loss (Cann et al 1987;Devogelaer et al 1987;Matta et al 1987).…”
Section: Discussionmentioning
confidence: 98%
See 1 more Smart Citation
“…There is concern that increased long-term use of LHRH analogues may be associated with unwanted sequelae of hypoestrogenism, such as osteopaenia (McLachlan et al 1986;Gudmundsson et al 1987;Henzl et al 1988). Our present findings in the rat con¬ firm, by direct skeletal analysis, work in women which suggests that LHRH agonists cause bone loss (Cann et al 1987;Devogelaer et al 1987;Matta et al 1987).…”
Section: Discussionmentioning
confidence: 98%
“…Currently, there is widespread con¬ cern that increased prolonged use of these agonists to treat endometriosis will cause sustained oestrogendeficiency bone loss in young women of premenopausal age (McLachlan, Healy & Burger, 1986;Cann, Henzl, Burry et al 1987;Devogelaer, Nagant de Deuxchaisnes, Donnez & Thomas, 1987;Gudmundsson, Ljunghall, Bergquist et al 1987;Matta, Shaw, Hesp & Katz, 1987;Henzl, Corson, Moghissi et ai. 1988).…”
mentioning
confidence: 97%
“…We have demonstrated in a longitudinal study that when buserelin was administered intranasally, 400 pg three times daily, to 13 premenopausal women there was an associated small but significant reduction of 6% in their mean lumbar vertebral trabecular bone density at the end of 6 months treatment; this loss was reversed 6 months after discontinuation of therapy (Matta et al 1987;Matta et al 1088h). For the same reason we have reservations about advocating the use of LHRH agonists in perimenopausal symptomatic women (McLachlan et al 1986;Van Leusden 1986;Rolland et al 1986;Friedman et al 1987) with the aim of controlling their symptoms until natural occurrence of the menopause. Accelerated bone loss occurs in oophorectomized premenopausal women and in all postmenopausal women; it is minimized by oestrogen therapy.…”
Section: Discussionmentioning
confidence: 99%
“…This time of commencement, however, rules out the possibility of accidental administration during pregnancy. When begun in the luteal phase of the menstrual cycle, the elevation of gonadotrophins and sex steroids is restricted to this phase and normal menstruation occurs without a subsequent withdrawal blced in the following cycle (Fraser & Sandow 1985;Hcaly et al 1986;McLachlan et al 1986).…”
Section: Luteinizing Hormone-releasing Hormone ( L H R H ) Analoguesmentioning
confidence: 99%